Q2 2026 Ardelyx, Inc. Earnings Call Transcript
Key Points
- Ardelyx Inc (ARDX) achieved record quarterly revenue of $118 million in Q2 2026, up 31% year-over-year, driven by strong demand for both Ibsrela and Xphozah.
- Ibsrela revenue grew 33% year-over-year to $86.2 million, with record-high demand, total prescriptions, and market share since launch, reinforcing confidence in the $1 billion revenue potential.
- Xphozah demonstrated resilience with 27% year-over-year revenue growth to $31.9 million, driven by strong demand and increased total dispenses and paid prescriptions.
- The company is well-funded with $281.8 million in cash and short-term investments, and is on track to achieve sustainable profitability in 2027, with net losses narrowing to $16.7 million in Q2.
- Ardelyx is advancing its pipeline, including tenapanor and the next-generation NHE3 inhibitor, and has built a robust patent estate for tenapanor with protection through 2042.
- The company is taking proactive measures to address payer hurdles, including doubling its field reimbursement team, expanding its sales force to 144 representatives, and enhancing the Ibsrela Pharmacy Network to improve fulfillment rates and adherence.
- Ardelyx Inc (ARDX) lowered its full-year 2026 Ibsrela revenue guidance to $350-$370 million due to significant payer-imposed hurdles, including more stringent step edits and prior authorizations, which have slowed new patient starts.
- The company withdrew its $750 million revenue guidance for Xphozah due to market uncertainty, including the end of the TDAPA period and the implementation of a new phosphorus quality incentive program, which could impact future growth.
- The DC Circuit Court of Appeals affirmed the dismissal of the lawsuit against CMS, keeping oral phosphate-lowering drugs in the bundle, which presents ongoing challenges for Xphozah's market access.
- Operating expenses increased significantly, with SG&A expenses rising to $101.4 million in Q2 2026, reflecting deliberate investments to address access barriers, which may pressure near-term profitability.
- The company drew down $50 million from its SLR arrangement for general corporate purposes, increasing debt and potentially impacting financial flexibility.
- The revised guidance implies a need for significant sequential revenue growth in the second half of 2026, which may be challenging given the persistent payer hurdles and market dynamics.
Welcome to the Ardelix Second Quarter 2026 Earnings Call. All participants will be in a listen-only mode. I would now like to turn the conference over to Lisa Caparelli, Senior Vice President of Investor Relations and Corporate Communications. Lisa, you may begin.
Thank you, Jen. Good afternoon, everyone, and welcome to our second quarter 2026 financial results and business update call.
Earlier today, we issued our earnings release, which can be found on the Investor section of our website at ardelix.com. Slides that accompany today's call will also be found on our website.
On today's call, I am joined by Mike Raab, President and CEO of Ardelix Eric Foster, Chief Commercial Officer and Sue Hohenleitner, our Chief Financial Officer.
Before we begin, I'd like to remind you that some of the statements made during the call today and forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1,995.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
